Efficacy of COVID-19 vaccines in inflammatory bowel disease patients receiving anti-TNF therapy : A systematic review and meta-analysis
© 2023 Published by Elsevier Ltd..
Background and objectives: There are concerns about the serological responses to Coronavirus disease 2019 (COVID-19) vaccines in inflammatory bowel disease (IBD) patients, particularly those receiving anti-TNF therapy. This study aimed to systematically evaluate the efficacy of COVID-19 vaccines in IBD patients receiving anti-TNF therapy.
Methods: Electronic databases were searched to identify relevant studies. We calculated pooled seroconversion rate after COVID-19 vaccination and subgroup analysis for vaccine types and different treatments were performed. Additionally, we estimated pooled rate of T cell response, neutralization response, and breakthrough infections in this population.
Results: 32 studies were included in the meta-analysis. IBD patients receiving anti-TNF therapy had relatively high overall seroconversion rate after complete vaccination, with no statistical difference in antibody responses associated with different drug treatments. The pooled positivity rate of T cell response was 0.85 in IBD patients receiving anti-TNF therapy. Compared with healthy controls, the positivity of neutralization assays was significantly lower in IBD patients receiving anti-TNF therapy. The pooled rate of breakthrough infections in IBD patients receiving anti-TNF therapy was 0.04.
Conclusions: COVID-19 vaccines have shown good efficacy in IBD patients receiving anti-TNF therapy. However, IBD patients receiving anti-TNF have a relatively high rate of breakthrough infections and a low level of neutralization response.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Heliyon - 9(2023), 9 vom: 28. Sept., Seite e19609 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dou, Dan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-TNF therapy |
|---|
| Anmerkungen: |
Date Revised 18.10.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.heliyon.2023.e19609 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363032290 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363032290 | ||
| 003 | DE-627 | ||
| 005 | 20231226092506.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.heliyon.2023.e19609 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1210.xml |
| 035 | |a (DE-627)NLM363032290 | ||
| 035 | |a (NLM)37810049 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dou, Dan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of COVID-19 vaccines in inflammatory bowel disease patients receiving anti-TNF therapy |b A systematic review and meta-analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.10.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 Published by Elsevier Ltd. | ||
| 520 | |a Background and objectives: There are concerns about the serological responses to Coronavirus disease 2019 (COVID-19) vaccines in inflammatory bowel disease (IBD) patients, particularly those receiving anti-TNF therapy. This study aimed to systematically evaluate the efficacy of COVID-19 vaccines in IBD patients receiving anti-TNF therapy | ||
| 520 | |a Methods: Electronic databases were searched to identify relevant studies. We calculated pooled seroconversion rate after COVID-19 vaccination and subgroup analysis for vaccine types and different treatments were performed. Additionally, we estimated pooled rate of T cell response, neutralization response, and breakthrough infections in this population | ||
| 520 | |a Results: 32 studies were included in the meta-analysis. IBD patients receiving anti-TNF therapy had relatively high overall seroconversion rate after complete vaccination, with no statistical difference in antibody responses associated with different drug treatments. The pooled positivity rate of T cell response was 0.85 in IBD patients receiving anti-TNF therapy. Compared with healthy controls, the positivity of neutralization assays was significantly lower in IBD patients receiving anti-TNF therapy. The pooled rate of breakthrough infections in IBD patients receiving anti-TNF therapy was 0.04 | ||
| 520 | |a Conclusions: COVID-19 vaccines have shown good efficacy in IBD patients receiving anti-TNF therapy. However, IBD patients receiving anti-TNF have a relatively high rate of breakthrough infections and a low level of neutralization response | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-TNF therapy | |
| 650 | 4 | |a COVID-19 vaccines | |
| 650 | 4 | |a Inflammatory bowel disease | |
| 650 | 4 | |a Meta-analysis | |
| 650 | 4 | |a Serological response | |
| 700 | 1 | |a Zhang, Fangyi |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Shuqing |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Xingyu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Xihan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Dianpeng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Shengsheng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Luqing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Heliyon |d 2015 |g 9(2023), 9 vom: 28. Sept., Seite e19609 |w (DE-627)NLM255913095 |x 2405-8440 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2023 |g number:9 |g day:28 |g month:09 |g pages:e19609 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.heliyon.2023.e19609 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2023 |e 9 |b 28 |c 09 |h e19609 | ||